Simufilam misses key endpoints again, prompting Cassava to phase out Alzheimer's program and shift to new indications ...

Under the terms of the agreements, Sava Re will provide up to $10m (€9.25m) in line size for ASR's core classes.

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA) stands against other best ...

Cassava Sciences, Inc. (SAVA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Cassava Sciences, Inc. (SAVA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...